




Mechanical Thrombectomy revolutionized the treatment of ischemic stroke

- Proven efficacy up to 24h by randomized controlled trials
- Could benefit up to 1/3 of all ischemic stroke patients
- Reperfusion obtained by mechanical thrombectomy with one of two device strategies:



Stentriever




Aspiration

Ischemic stroke can be caused by different clot types and different removal techniques exist



Stentriever




Aspiration


Clot type influences retrievability



Today: Unknown clot type requires a trial-and-error approach bearing grave risks for the patient



The smart stroke guidewire Clotild[®] analyzes the clot to provide decisive information for the retrieval strategy




Increasing the first-pass-effect: the new objective for mechanical thrombectomy


- Getting the clot out on the first pass and reestablishing (near) complete perfusion of the brain
 - Improves patient outcome
 - Lowers the risk of complications and mortality
 - Reduces the in-hospital cost by ~30% (~\$7000) and overall cost by 25%
- But today: First pass effect is achieved in about 1/3 of all cases

Sensome's technology to identify clot type






- Array of impedance sensors with incorporated proprietary micro-chip
- AI-powered signal processing algorithm



Low and high frequency currents enable characterization of clot composition




Machine learning algorithm sorts impedance patterns to recognize clots



Micro-electronics technology enables an unmatched miniaturization of our sensor technology





CLOTILD[®] SMART STROKE GUIDEWIRE TO DIFFERENTIATE CLOTS

Clotild[®] is currently not approved anywhere in the world.

Clotild[®] smart guidewire
crossing a red-blood-cell-rich clot
vs.
crossing a fibrin-rich clot


Clotild[®] is currently not approved anywhere in the world.

Click above to watch the video!

Successfully tested Clotild® in vivo



The Clotbase project: Clotomir is paving the way for Clotild



- Ex-vivo platform mimicking Clotild's sensor
- Create a comprehensive database of hundreds of (real-world) retrieved clots
 - Identify optimal retrieval strategy for each clot during acute stroke
 - Determine clot origin
- Inform and prepare the algorithm for Clotild
- Pilot study at 4 hospitals with focus on histology and collected over 150 clots is wrapping up demonstrating excellent performance of Sensome's algorithms on real-world data
- Next steps: collect 500+ clots until Q2 of 2022

Data
science

quality

10 Ph.D.s

micro
electronics

biology

19
people

14
engineers

micro
fabri
cation

7
nationalities

2 complementary Boards to guide Sensome's development

Science

Jacques Moret, MD, PhD
Bicetre Hospital

Pioneer of neurovascular interventions



Laurent Spelle, MD, PhD
Bicetre Hospital

Chairman and co-founder NEURI, co-organizer of LINNC



Christophe Cognard, MD, PhD
Purpan Hospital

Investigator of SWIFT PRIME Trial



Vitor Pereira, MD, PhD
Toronto Western Hospital

Global principal investigator of STAR Trial



Abdul Barakat, PhD
CSA & co-founder

Biomechanics & atherosclerosis expert
AXA Chair holder



Ulrich Sigwart, MD, PhD
emer. University of Geneva

Pioneer of vascular stenting



Business

Franz Bozsak, PhD
founding CEO & president

Founders



Florian Reinaud, MD
Medical entrepreneur

Business Angels



Philippe Peltier
Kurma Partners Partner

Venture Capital



Gonzague Issenmann
Medtech entrepreneur

Independent



Sensome's financing story so far

2014

Sensome founded, team of 4,
200k€ from Concours Mondial
d'Innovation

2016

Change of indication: from
heart attack to ischemic stroke

2018

5m€ Series A financing: BNP
Paribas joins historic investors

2015

First animal trial and 1m€ pre-
seed financing from Business
Angels

2017

3m€ Seed financing round with
VCs (led by Kurma Partners)

2020

8m€ Series B financing and
conclusion of a R&D partnership
with Asahi Intecc

SENSOME powered

smart medical devices to revolutionize tomorrow's healthcare

